ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)

News   Oct 09, 2009

 
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
 
 
 

RELATED ARTICLES

PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug Discovery

News

Investment to fund expansion of operations and progression of drug target pipeline.

READ MORE

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites

News

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

READ MORE

CBD Significantly Reduces Seizures in Patients with Severe Form of Epilepsy

News

Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE